• Eisai and Biogen received accelerated approval for their Alzheimer's treatment in the U.S. at an annual cost of $26,500.
  • Goldman Sachs will cut about 3,200 jobs this week as part of a restructuring program, according to Bloomberg.
  • Qatar Energy and Chevron are partnering in a $6 billion petrochemical plant.
  • Stora Enso completed the acquisition of De Jong Packaging Group for €1.02 billion.
  • Silchester becomes WPP's third largest shareholder and may ask for the removal of the chairman of the board.
  • Alibaba plans to invest $1bn in Turkey.
  • FDA reports potential ineffectiveness of AstraZeneca's COVID-19 drug against the new Omicron sub-variant. AstraZeneca to acquire CinCor Pharma for $1.8 billion.
  • Sartorius AG CEO expects less technological opening with China.
  • Autoneum acquires Borgers for €117 million.
  • Qiagen acquires Verogen for $150M.
  • Otsuka and Lundbeck gets FDA priority review for Brexpiprazole for the treatment of agitation associated with Alzheimer's dementia.
  • Macy's estimates Q4 2022 revenue at the low end of guidance.
  • Jack Ma no longer controls Ant Group.
  • Oracle, Verizon, AT&T, Intuit, Repsol, Equinor and Barry Callebaut detach dividends.
  • Tesla announced Monday an extension of delivery times for some of its Y models in China, a sign of increased demand after the recent price cut.
  • Chevron and Exxon Mobil were up about 1.5% in premarket trading as oil prices rose following the reopening of China's borders on Sunday.
  • Macy's expects to report lower-than-expected fourth-quarter sales and limited spending in 2023 due to inflation.
  • Salesforce is looking to save $3 billion to $5 billion, CEO Marc Benioff told employees, Fortune magazine reported Friday, citing an audio recording of the meeting.
  • Moderna - COVID-19 vaccine sales were $18.4 billion in 2022, in line with the group's forecast.
  • CVS expects to post annual sales above its expectations of $309 billion to $314 billion and adjusted earnings per share at the high end of its guidance.
  • Abercrombie & Fitch raised its sales guidance for the last three months of 2022.
  • Lululemon Athletica lost 10% in premarket trading after announcing it expects gross margins to decline in the fourth quarter, hurt by inflation.
  • China will not include Pfizer's COVID-19 antiviral Paxlovid on its list of treatments covered by medical insurance plans because of its high price.
  • Biopharmaceutical company Cincor is to be bought by AstraZeneca for up to $1.8 billion, the Anglo-Swedish company announced Monday.